Percutaneous interventions on the hemodialysis reliable outflow vascular access device

J Vasc Interv Radiol. 2013 Apr;24(4):543-9. doi: 10.1016/j.jvir.2012.12.027. Epub 2013 Feb 23.

Abstract

Purpose: To determine the outcomes of percutaneous interventions for prolonging the patency of the Hemodialysis Reliable Outflow (HeRO) device.

Materials and methods: Between January 2007 and August 2011, 73 percutaneous interventions were performed on 26 HeRO devices in 25 patients. The graft was implanted in the upper arm with the outflow catheter tip in the superior vena cava or right atrium. Procedural reports, angiographic images, and clinical notes were retrospectively reviewed. The primary and secondary patency rates after intervention were calculated using the Kaplan-Meier method.

Results: The mean time from HeRO implantation to initial dysfunction or thrombosis was 171 days. In 60 (82%) procedures, the HeRO device was thrombosed. An intragraft stenosis was the most common lesion identified (59%; n = 43) followed by an arterial anastomosis stenosis identified in 18% (n = 13). In 22% (n = 16) of procedures in which the HeRO device was thrombosed, an underlying cause was not identified after thrombectomy. The 3-, 6-, and 12-month primary patency rates after intervention were 47%, 37%, and 26% for first-time interventions. The secondary patency rates were 80%, 70%, and 64%. The only complication was pulmonary embolism resulting in death 2 days after HeRO thrombectomy.

Conclusions: Percutaneous interventions on thrombosed and failing HeRO devices yielded acceptable primary and secondary patency rates after intervention in these patients with few, if any, alternatives for hemodialysis access.

MeSH terms

  • Angiography, Digital Subtraction
  • Angioplasty, Balloon
  • Arteriovenous Shunt, Surgical / adverse effects
  • Arteriovenous Shunt, Surgical / instrumentation*
  • Blood Vessel Prosthesis Implantation / instrumentation*
  • Blood Vessel Prosthesis*
  • Central Venous Catheters*
  • Constriction, Pathologic
  • Endovascular Procedures*
  • Equipment Design
  • Equipment Failure
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Graft Occlusion, Vascular / diagnosis
  • Graft Occlusion, Vascular / etiology
  • Graft Occlusion, Vascular / physiopathology
  • Graft Occlusion, Vascular / therapy*
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Prosthesis Design
  • Prosthesis Failure
  • Renal Dialysis*
  • Retrospective Studies
  • Thrombectomy
  • Thrombolytic Therapy
  • Time Factors
  • Tissue Plasminogen Activator / administration & dosage
  • Treatment Outcome
  • Upper Extremity / blood supply*
  • Upper Extremity Deep Vein Thrombosis / diagnosis
  • Upper Extremity Deep Vein Thrombosis / etiology
  • Upper Extremity Deep Vein Thrombosis / physiopathology
  • Upper Extremity Deep Vein Thrombosis / therapy*
  • Vascular Patency

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator